Comparative Pharmacology
Head-to-head clinical analysis: PHILITH versus QUARTETTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHILITH versus QUARTETTE.
PHILITH vs QUARTETTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PHILITH is a combined oral contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, while drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity, inhibiting ovulation and altering cervical mucus.
Combination oral contraceptive containing drospirenone, ethinyl estradiol, levomefolate calcium, and metformin. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity. Ethinyl estradiol is an estrogen. Levomefolate calcium is a folate supplement. Metformin is a biguanide that decreases hepatic glucose production and improves insulin sensitivity.
1 mg orally once daily
3 mg orally once daily for 21 days followed by 7 days of placebo.
None Documented
None Documented
Terminal half-life 12 hours; clinically relevant for twice-daily dosing with steady state reached after 2-3 days.
Terminal elimination half-life is 12-14 hours; clinically this supports once-daily dosing with steady state achieved within 2-3 days.
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Renal excretion accounts for 55% (primarily as unchanged drug), biliary/fecal excretion 35%, and the remainder undergoes metabolic clearance.
Category C
Category C
Oral Contraceptive
Oral Contraceptive